Condoliase - Seikagaku Corporation

Drug Profile

Condoliase - Seikagaku Corporation

Alternative Names: C-ABC; ChABC; Chondroitin-sulfate-ABC endolyase; Chondroitinase ABC; SI-6603

Latest Information Update: 16 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Seikagaku Corporation
  • Class Chondroitin lyases
  • Mechanism of Action Chondroitin sulfate proteoglycan modulators; Glycosaminoglycan modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Intervertebral disc displacement

Most Recent Events

  • 19 Feb 2018 Seikagaku Corporation plans to initiate an additional phase III trial for Intervertebral disc displacement in USA in the second quarter of 2018
  • 07 Nov 2017 Seikagaku Corporation completes a phase III trial for Intervertebral disc displacement in USA (Intraspinal, Injection) (NCT01941563)
  • 07 Nov 2017 Seikagaku intends to initiate a III, double-blind clinical trial for Intervertebral disc displacement in USA at an early date
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top